These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1421034)

  • 1. Serum erythropoietin levels in hemodialysed patients after administration of recombinant human erythropoietin.
    Pavlović-Kentera V; Clemons GK; Biljanović-Paunović L; Marisavljević D; Lezaić V; Pokrajac M; Djukanović L
    Biomed Pharmacother; 1992; 46(1):37-43. PubMed ID: 1421034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
    Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
    ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin.
    Jensen JD; Madsen JK; Jensen LW
    Eur J Clin Pharmacol; 1996; 50(3):171-7. PubMed ID: 8737755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients.
    Parker KP; Mitch WE; Stivelman JC; Macon EJ; Bailey JL; Sands JM
    J Am Soc Nephrol; 1997 Feb; 8(2):288-93. PubMed ID: 9048348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
    Carlini R; Obialo CI; Rothstein M
    Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients.
    Albitar S; Meulders Q; Hammoud H; Soutif C; Bouvier P; Pollini J
    Nephrol Dial Transplant; 1995; 10 Suppl 6():40-3. PubMed ID: 8524493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of a polyacrylonitrile membrane and a membrane made of regenerated cellulose on the plasma concentrations of erythropoietin during hemodialysis.
    Opatrný K; Krouzecký A; Wirth J; Vít L; Eiselt J
    Artif Organs; 1998 Oct; 22(10):816-20. PubMed ID: 9790077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet.
    Allegra V; Martimbianco L; Vasile A
    Nephrol Dial Transplant; 1997 May; 12(5):924-32. PubMed ID: 9175044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin.
    Barclay PG; Fischer ER; Harris DC
    Clin Nephrol; 1993 Nov; 40(5):277-80. PubMed ID: 8281716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia.
    Piron M; Loo M; Gothot A; Tassin F; Fillet G; Beguin Y
    Blood; 2001 Jan; 97(2):442-8. PubMed ID: 11154221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intramuscular versus subcutaneous erythropoietin for the treatment of anemia in CAPD patients.
    Abreo K; Lubom JA; Collier L; Fleming D; Work J
    Adv Perit Dial; 1994; 10():124-8. PubMed ID: 7999809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia.
    Mittelman M; Zeidman A; Fradin Z; Magazanik A; Lewinski UH; Cohen A
    Acta Haematol; 1997; 98(4):204-10. PubMed ID: 9401498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.
    Muirhead N; Churchill DN; Goldstein M; Nadler SP; Posen G; Wong C; Slaughter D; Laplante P
    Am J Nephrol; 1992; 12(5):303-10. PubMed ID: 1488998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of anemia in W/WV mice by recombinant human erythropoietin (rHuEPO) mediated through EPO receptors with lowered affinity.
    Kabaya K; Akiyama H; Nishi N; Misaizu T; Okada Y; Kawagishi M; Amano K; Kusaka M; Seki M; Uzumaki H
    Life Sci; 1995; 57(11):1067-76. PubMed ID: 7658914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
    Lui SF; Chung WW; Leung CB; Chan K; Lai KN
    Clin Nephrol; 1990 Jan; 33(1):47-51. PubMed ID: 2302870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leptin and serum erythropoietin in hemodialyzed and peritoneally dialyzed uremic patients during rHuEPO therapy.
    Małyszko J; Zbroch E; Wołczyński S; Małyszko JS; Hryszko T; Myśliwiec M
    Am J Nephrol; 2000; 20(3):180-6. PubMed ID: 10878398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation.
    Van Biesen W; Vanholder R; Veys N; Verbeke F; Lameire N
    Transplantation; 2005 Feb; 79(3):367-8. PubMed ID: 15699772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Does long-term erythropoietin therapy influence the prevalence of serum markers of hepatitis B and C in haemodialysed uraemic patients?].
    Mesjasz J; Wiecek A; Gonciarz Z; Mazur W; Kokot F
    Pol Merkur Lekarski; 2004 Apr; 16(94):362-7. PubMed ID: 15517934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
    Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
    Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to Erythropoietin Are Associated with Erythropoietin Resistance in Hemodialysis Patients in KwaZulu-Natal (South Africa).
    Benjamin S; Adam J; Naidu Krishna SB; Assounga AG
    Saudi J Kidney Dis Transpl; 2020; 31(5):917-926. PubMed ID: 33229756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.